Fortress Biotech (NASDAQ: FBIO) and Onconova Therapeutics (NASDAQ:ONTX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, earnings, institutional ownership, risk, dividends and valuation.

Risk and Volatility

Fortress Biotech has a beta of 1.15, meaning that its share price is 15% more volatile than the S&P 500. Comparatively, Onconova Therapeutics has a beta of 0.18, meaning that its share price is 82% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings for Fortress Biotech and Onconova Therapeutics, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Fortress Biotech 0 0 4 0 3.00
Onconova Therapeutics 0 0 4 0 3.00

Fortress Biotech currently has a consensus price target of $11.00, indicating a potential upside of 194.12%. Onconova Therapeutics has a consensus price target of $7.33, indicating a potential upside of 266.67%. Given Onconova Therapeutics’ higher possible upside, analysts plainly believe Onconova Therapeutics is more favorable than Fortress Biotech.

Valuation and Earnings

This table compares Fortress Biotech and Onconova Therapeutics’ top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Fortress Biotech $108.97 million 1.73 -$71.48 million ($1.48) -2.53
Onconova Therapeutics $2.36 million 8.35 -$22.15 million ($2.35) -0.85

Onconova Therapeutics has higher revenue, but lower earnings than Fortress Biotech. Fortress Biotech is trading at a lower price-to-earnings ratio than Onconova Therapeutics, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

12.0% of Fortress Biotech shares are held by institutional investors. Comparatively, 26.8% of Onconova Therapeutics shares are held by institutional investors. 33.3% of Fortress Biotech shares are held by insiders. Comparatively, 27.3% of Onconova Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.


This table compares Fortress Biotech and Onconova Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Fortress Biotech -53.95% -54.88% -30.67%
Onconova Therapeutics -762.13% -558.97% -85.62%


Fortress Biotech beats Onconova Therapeutics on 7 of the 11 factors compared between the two stocks.

Fortress Biotech Company Profile

Fortress Biotech, Inc., formerly Coronado Biosciences, Inc., is a biopharmaceutical company. The Company is involved in the development of immunotherapy agents for the treatment of autoimmune diseases and cancer. Its sole product candidate is CNDO-109. The Company is also focused on acquiring, developing and commercializing pharmaceutical and biotechnology products. The Company’s product, CNDO-109, is a lysate (disrupted Closteroviridae (CTV)-1 cells, cell membrane fragments, cell proteins and other cellular components) that activates donor Natural Killer (NK) cells. CTV-1 is a leukemic cell line re-classified as a T-cell acute lymphocytic leukemia (ALL). The Company holds the license to develop and commercialize CNDO-109 to activate NK cells for the treatment of cancer-related and other conditions, and a non-exclusive license to certain clinical data solely for use in the Investigational new drug (IND) for CNDO-109. The Company is conducting the Phase I clinical studies of CNDO-109.

Onconova Therapeutics Company Profile

Onconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company operates through the identification and development of oncology therapeutics segment. It is focused on discovering and developing small molecule drug candidates to treat cancer. The Company has created a targeted anti-cancer agents designed to work against specific cellular pathways that are important to cancer cells. It has over three clinical-stage product candidates and various preclinical programs that target kinases, cellular metabolism or cell division in preclinical development. The Company’s lead product candidate, rigosertib, is being tested in both intravenous (IV) and oral formulations as a single agent, and the oral formulation is also being tested in combination with azacitidine, in clinical trials for patients with myelodysplastic syndromes (MDS), and related cancers. Its other product candidates include Briciclib and Recilisib.

Receive News & Ratings for Fortress Biotech Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fortress Biotech Inc. and related companies with's FREE daily email newsletter.